Published in Neurology on September 22, 1999
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology (2014) 6.73
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain (2010) 3.48
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain (2008) 3.05
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 2.75
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol (2012) 2.06
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology (2014) 1.80
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology (2011) 1.77
MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology (2015) 1.74
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol (2014) 1.60
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci (2007) 1.59
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics (2011) 1.57
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci (2014) 1.44
Neuromyelitis optica: atipic clinic presentation. Neurol Sci (2011) 1.39
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31
Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler (2015) 1.30
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol (2015) 1.26
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology (2012) 1.25
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One (2013) 1.21
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord (2011) 1.19
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology (2007) 1.16
Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm (2015) 1.15
Demographic and clinical features of neuromyelitis optica: A review. Mult Scler (2015) 1.14
Familial neuromyelitis optica. Neurology (2010) 1.14
Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol (2009) 1.14
Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol (2007) 1.12
A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci (2009) 1.12
Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol (2010) 1.11
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler (2012) 1.10
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol (2009) 1.10
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol (2012) 1.09
Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08
Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol (2008) 1.08
Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol (2008) 1.07
Clinical manifestations of neurological involvement in primary Sjögren’s syndrome. Clin Rheumatol (2011) 1.07
Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int (2012) 1.07
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Demyelinating disorder of the central nervous system occurring in black South Africans. J Neurol Neurosurg Psychiatry (2001) 1.07
White matter astrocytes in health and disease. Neuroscience (2013) 1.07
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci (2011) 1.06
Neuromyelitis optica and pregnancy. J Neurol (2013) 1.06
Optic neuritis. Eye (Lond) (2011) 1.05
Eugène Devic (1858-1930). J Neurol (2002) 1.05
Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. J Neurol (2007) 1.04
Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol (2013) 1.01
Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation (2010) 0.98
Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One (2011) 0.98
Association of neuromyelitis optica with severe and intractable pain. Arch Neurol (2012) 0.98
Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry (2002) 0.98
Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler (2012) 0.97
Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist (2013) 0.97
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96
Evaluating the use of optical coherence tomography in optic neuritis. Mult Scler Int (2011) 0.96
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol (2009) 0.96
Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete? Neuroradiology (2011) 0.95
Treatment of neuromyelitis optica: current debate. Ther Adv Neurol Disord (2008) 0.95
Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94
A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation (2010) 0.94
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol (2014) 0.94
The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care (2013) 0.94
Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol (2010) 0.93
Neuromyelitis Optica. Curr Treat Options Neurol (2005) 0.93
Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol (2013) 0.93
The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Int J Mol Sci (2016) 0.93
Current options for the treatment of optic neuritis. Clin Ophthalmol (2012) 0.92
Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci (2012) 0.92
Neuromyelitis optica - an update: 2007-2009. Ann Indian Acad Neurol (2009) 0.92
Acute transverse myelitis in demyelinating diseases among the Chinese. J Neurol (2011) 0.91
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol (2015) 0.91
Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol (2011) 0.91
Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One (2012) 0.90
Optic neuritis in neuromyelitis optica. Prog Retin Eye Res (2013) 0.90
Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci (2013) 0.89
A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iran J Neurol (2015) 0.89
Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype. J Neurol Neurosurg Psychiatry (2006) 0.89
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Multiple sclerosis. N Engl J Med (2000) 12.69
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Procedures for comparing samples with multiple endpoints. Biometrics (1984) 6.70
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Role of chemotaxis in the association of motile bacteria with intestinal mucosa: in vivo studies. Infect Immun (1981) 4.34
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology (1993) 4.18
Trauma and multiple sclerosis: a population-based cohort study from Olmsted County, Minnesota. Neurology (1993) 4.04
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc (1991) 3.88
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Designs for group sequential tests. Control Clin Trials (1984) 3.56
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin Proc (1971) 3.35
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Verifying the stroke-free phenotype by structured telephone interview. Stroke (2000) 3.15
The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. Neurology (1999) 3.09
Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology (2007) 2.93
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve (1997) 2.86
Role of chemotaxis in the association of motile bacteria with intestinal mucosa: in vitro studies. Infect Immun (1981) 2.76
Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol (1980) 2.75
Liver iron stores in patients with non-insulin-dependent diabetes mellitus. Mayo Clin Proc (1994) 2.71
Limitations of quantitative sensory testing when patients are biased toward a bad outcome. Neurology (1998) 2.70
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
Memory and MRI-based hippocampal volumes in aging and AD. Neurology (2000) 2.65
Value of autonomic testing in reflex sympathetic dystrophy. Mayo Clin Proc (1995) 2.65
Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol (1997) 2.60
Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA (2001) 2.53
Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg (1994) 2.50
Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology (1995) 2.42
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
1H MR spectroscopy in common dementias. Neurology (2004) 2.39
Role of chemotaxis in the association of motile bacteria with intestinal mucosa: fitness and virulence of nonchemotactic Vibrio cholerae mutants in infant mice. Infect Immun (1981) 2.39
Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN. Neurology (1998) 2.38
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease. J Clin Epidemiol (1996) 2.27
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology (2000) 2.26
FLAIR histogram segmentation for measurement of leukoaraiosis volume. J Magn Reson Imaging (2001) 2.24
Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology (1997) 2.23
Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology (2003) 2.10
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Role of chemotaxis in the association of motile bacteria with intestinal mucosa: chemotactic responses of Vibrio cholerae and description of motile nonchemotactic mutants. Infect Immun (1981) 1.97
Cardiac surgery in the octogenarian: perioperative outcome and clinical follow-up. J Am Coll Cardiol (1991) 1.96
The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg (1976) 1.93
Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology (2001) 1.92
The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics (1983) 1.89
Magnetic resonance imaging-based volume studies in temporal lobe epilepsy: pathological correlations. Ann Neurol (1991) 1.89
Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol (1998) 1.86
Effect of chemotaxis on the interaction of cholera vibrios with intestinal mucosa. Am J Clin Nutr (1979) 1.85
Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology (1991) 1.84
A complete comparative chromosome map for the dog, red fox, and human and its integration with canine genetic maps. Genomics (1999) 1.79
Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology (1995) 1.78
Assessment of body composition with use of dual-energy x-ray absorptiometry: evaluation and comparison with other methods. Mayo Clin Proc (1993) 1.77
Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem (1992) 1.77
Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol (1982) 1.77
Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care (1999) 1.74
Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology (1998) 1.72
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (1994) 1.68
Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology (2011) 1.64
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology (1993) 1.57
A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet (2000) 1.54
Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology (1976) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Population-based study of seizure disorders after cerebral infarction. Neurology (1996) 1.52
Methods for assessment of the rate of onset and offset of insulin action during nonsteady state in humans. Am J Physiol (1993) 1.52
Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology (2004) 1.51
Magnetic resonance image-based hippocampal volumetry: correlation with outcome after temporal lobectomy. Ann Neurol (1992) 1.49
Theophylline effect on sleep in normal subjects. Chest (1993) 1.47
A window of opportunity for no treatment in early multiple sclerosis? Mult Scler (2010) 1.45
Measurements of glucose control. Diabetes Care (1987) 1.45
Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J (1980) 1.44
Complete ophthalmoplegia as a complication of acute corticosteroid- and pancuronium-associated myopathy. Neurology (1991) 1.44
Diagnostic interpretation of the intravenous tolbutamide test for insulinoma. Mayo Clin Proc (1989) 1.43
The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology (1991) 1.43
The therapeutic impact of temporal artery biopsy. Lancet (1983) 1.42
Comparison of techniques to estimate total body skeletal muscle mass in people of different age groups. Am J Physiol (1999) 1.42
Introduction of automated systems to evaluate touch-pressure, vibration, and thermal cutaneous sensation in man. Ann Neurol (1978) 1.42
Paraneoplastic encephalomyelitis and seminoma: importance of testicular ultrasonography. Neurology (1998) 1.42
Cutaneous malignant melanoma in Rochester, Minnesota: trends in incidence and survivorship, 1950 through 1985. Mayo Clin Proc (1990) 1.42
Prevalence of monoclonal protein in peripheral neuropathy. Neurology (1981) 1.41
DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2005) 1.41
Tropicamide eyedrops cannot be used for reliable diagnosis of Alzheimer's disease. Mayo Clin Proc (1997) 1.40
HTLV-1 associated myelopathy in Canada. Can J Neurol Sci (1989) 1.40
Predictors of outcome of anterior temporal lobectomy for intractable epilepsy: a multivariate study. Neurology (1998) 1.39
Late survival after abdominal aortic aneurysm repair: influence of coronary artery disease. J Vasc Surg (1984) 1.38
The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology (1992) 1.38
The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia (2001) 1.37
Referral selection bias in the Medicare hospital mortality prediction model: are centers of referral for Medicare beneficiaries necessarily centers of excellence? Health Serv Res (1994) 1.37
Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc (2000) 1.37